Safety and Feasibility Assessment of the Bio-electrical One Day Capsule System in Overweight and Class I Obese Participants
Primary Purpose
Overweight and Obesity
Status
Suspended
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
ODC system (type 1 capsule)
ODC system (type 2 capsule)
Sponsored by

About this trial
This is an interventional treatment trial for Overweight and Obesity
Eligibility Criteria
Inclusion Criteria:
- Age of 21-65 years old at time of screening
- Body mass Index (BMI) >= 27 and <35
- The subject has been under routine care of the investigator or another single physician that can supply a medical record for at least 4 months prior to enrollment
- Female subjects at reproductive age that are tested negative for pregnancy
- Women with childbearing potential (i.e., not post-menopausal or surgically sterilized) must agree to use adequate birth control methods during the whole study duration
- No significant weight loss (<5%) within four months prior to enrollment (by self -report)
- No recorded or treated psychological disorder(s) for at least six months prior to enrollment (by self report)
- Not taking anti-depressant medication, for at least six months prior to enrollment.
- Willingness to refrain from using prescription, over the counter or herbal weight loss products for the duration of he trial.
- Personally motivated and willing to comply with all the requirements of the clinical trial
- Able to understand, read and voluntary sign the inform consent form
- Agree and able to sign the consent form for the Pillcam(R) patency capsule test as is in use at Meir MC.
Exclusion Criteria:
- History o abdominal or gastrointestinal surgery (appendectomy, hernia repair, gynecological surgeries and cholecystectomy more than a year ago are allowed)
- Prior bariatric surgery
- Implanted electrical stimulation devices (e.g. pacemaker, defibrillator, neurostimulator)
- Unwillingness to stop medication altering gastric pH and/or affecting GI motility during the entire study duration.
- Known diagnosed psychiatric conditions that may impair subject's ability to comply with the study procedures (by self-report)
- Use of anti-psychotic medications
- Diagnosed with an eating disorder including bulimia and binge eating
- Swallowing difficulties
- Significant active or unstable acute or chronic illnesses/ diseases including gastrointestinal, systemic (non-gastrointestinal) and psychiatric conditions
- Use of another investigation device or agent in the 30 days prior to enrollment
- Women who are pregnant, lactating or anticipate to becoming pregnant within the study duration
- Planned or contemplated use of Magnetic Resonance Imaging (MRI) or any (e.g. oncologic) radiation during the course of the trial.
- Have a family member who is currently participating in this clinical trial
- Any other conditions that, in the opinion of the investigator, would make the subject unsuitable for the study
Sites / Locations
- Meir Medical Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Experimental
Arm Label
Gastric electrical stimulation with type 2 ODC
Electrical stimulation with type 2 ODC
Electrical stimulation with type 1 ODC
Arm Description
Safety and feasibility assessment of the ODC system (type 2) capsule during and following gastric electrical stimulation protocol.
Safety and feasibility assessment of the ODC system (type 2) capsule during and following small and large bowel electrical stimulation protocol.
Safety and feasibility assessment of the ODC system (type 1 capsule) during and following small and large electrical stimulation protocol.
Outcomes
Primary Outcome Measures
Occurrence and severity of all adverse events
Safety evaluation
Incidence of device-related adverse events
Safety evaluation
Incidence of clinically significant abnormal laboratory values as determined by the investigator
Safety evaluation
Excretion of the study capsules in a natural manner
Safety evaluation - confirmation of the capsule excretion from the body
Secondary Outcome Measures
Satiety levels
Changes in satiety levels resulting of the electrical stimulation
Appetite levels
Changes in appetite levels resulting of the electrical stimulation
Postprandial symptoms
Evaluation of postprandial symptoms during the treatment period
Response to nutrient drink test
Determination of the maximum tolerable drinking volume followed by postprandial symptoms measurement
Appetite-related hormone
Evaluation of appetite- related hormones levels change as a result of the stimulation applied
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT03734081
Brief Title
Safety and Feasibility Assessment of the Bio-electrical One Day Capsule System in Overweight and Class I Obese Participants
Official Title
A First in Human (FIH) Study to Assess the Safety and Feasibility of the Bio-electrical One Day Capsule (ODC) System (Type 1 and 2 Capsules) in Overweight and Class 1 Obese Subjects
Study Type
Interventional
2. Study Status
Record Verification Date
December 2018
Overall Recruitment Status
Suspended
Why Stopped
The first cohort of 6 subjects that has been enrolled is being analyzed and evaluated on all safety parameters as described in the study protocol.
Study Start Date
February 4, 2019 (Actual)
Primary Completion Date
December 2019 (Anticipated)
Study Completion Date
March 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Melcap Systems Ltd.
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The study represents the first effort to prospectively investigate the Melcap's bio-electrical ingestible ODC system in human. The study goal is to evaluate the safety and feasibility of GES treatment in stomach and in the small and large bowel during and following the ingestion of the bio-electrical capsule under tight and controlled conditions.
Detailed Description
The problem of obesity in the adult population requires the exploration and development of new, safe and effective therapies to combat increasing growth. A novel Implantable Gastric Electrical Stimulation (GES), MEASTRO(R) Rechargeable System, has been recently approved by the American Food and Drug Administration (FDA) for use in weight reduction in patients aged 18 years through adulthood who have a Body Mass Index (BMI) of 40 to 45 kg/m2 with one or more obesity related co-morbid conditions, and have failed at least one supervised management program within the past 5 years.
Melcap System Ltd. has developed an innovative ingestible capsule system device that uses GES for the treatment of overweight and obesity. The system is intended to suppress hunger, reduce appetite, increase satiation and promote weight reduction in overweight and class I obese adults who have a Body Mass Index of 27 kg/m2 to 34.9 kg/m2 with no related co-morbid conditions.
The study is a FIH prospective, open label, randomized study. It will include a 3 days screening period and 4 days treatment session under a close supervision and follow up. Each subject will ingest a total of 2 capsules (ODC) on the first and the third day of the study. The total duration of subject participation including the termination visit will be eight days.
The study will be conducted at a single medical center, Meir Hospital, Israel.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overweight and Obesity
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
12 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Gastric electrical stimulation with type 2 ODC
Arm Type
Experimental
Arm Description
Safety and feasibility assessment of the ODC system (type 2) capsule during and following gastric electrical stimulation protocol.
Arm Title
Electrical stimulation with type 2 ODC
Arm Type
Experimental
Arm Description
Safety and feasibility assessment of the ODC system (type 2) capsule during and following small and large bowel electrical stimulation protocol.
Arm Title
Electrical stimulation with type 1 ODC
Arm Type
Experimental
Arm Description
Safety and feasibility assessment of the ODC system (type 1 capsule) during and following small and large electrical stimulation protocol.
Intervention Type
Device
Intervention Name(s)
ODC system (type 1 capsule)
Intervention Description
ODC (one day capsule) type 1 is ingested by a subject and passes through the gastrointestinal tract. Electrical stimulation is the transferred from the capsule to the surrounding GI tissues. The capsule is excreted from the body through the intestinal tract in a natural manner with bowel movement.
Intervention Type
Device
Intervention Name(s)
ODC system (type 2 capsule)
Intervention Description
ODC (one day capsule) type 2 is ingested by a subject and passes through the gastrointestinal tract. Electrical stimulation is the transferred from the capsule to the surrounding GI tissues. The capsule is excreted from the body through the intestinal tract in a natural manner with bowel movement.
Primary Outcome Measure Information:
Title
Occurrence and severity of all adverse events
Description
Safety evaluation
Time Frame
During the whole study duration (approximately 8 days)
Title
Incidence of device-related adverse events
Description
Safety evaluation
Time Frame
During the whole study duration (approximately 8 days)
Title
Incidence of clinically significant abnormal laboratory values as determined by the investigator
Description
Safety evaluation
Time Frame
During the whole study duration (approximately 8 days)
Title
Excretion of the study capsules in a natural manner
Description
Safety evaluation - confirmation of the capsule excretion from the body
Time Frame
up to 3 days after the days of the capsules ingestion
Secondary Outcome Measure Information:
Title
Satiety levels
Description
Changes in satiety levels resulting of the electrical stimulation
Time Frame
Day #1 and #3 of the treatment period
Title
Appetite levels
Description
Changes in appetite levels resulting of the electrical stimulation
Time Frame
Day #1 and #3 of the treatment period
Title
Postprandial symptoms
Description
Evaluation of postprandial symptoms during the treatment period
Time Frame
Day #1, #2, #3 and #4 of the treatment period
Title
Response to nutrient drink test
Description
Determination of the maximum tolerable drinking volume followed by postprandial symptoms measurement
Time Frame
Day #3 of the screening period and and day #4 of the treatment period
Title
Appetite-related hormone
Description
Evaluation of appetite- related hormones levels change as a result of the stimulation applied
Time Frame
Day #1 and Day #3 of the treatment period
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Age of 21-65 years old at time of screening
Body mass Index (BMI) >= 27 and <35
The subject has been under routine care of the investigator or another single physician that can supply a medical record for at least 4 months prior to enrollment
Female subjects at reproductive age that are tested negative for pregnancy
Women with childbearing potential (i.e., not post-menopausal or surgically sterilized) must agree to use adequate birth control methods during the whole study duration
No significant weight loss (<5%) within four months prior to enrollment (by self -report)
No recorded or treated psychological disorder(s) for at least six months prior to enrollment (by self report)
Not taking anti-depressant medication, for at least six months prior to enrollment.
Willingness to refrain from using prescription, over the counter or herbal weight loss products for the duration of he trial.
Personally motivated and willing to comply with all the requirements of the clinical trial
Able to understand, read and voluntary sign the inform consent form
Agree and able to sign the consent form for the Pillcam(R) patency capsule test as is in use at Meir MC.
Exclusion Criteria:
History o abdominal or gastrointestinal surgery (appendectomy, hernia repair, gynecological surgeries and cholecystectomy more than a year ago are allowed)
Prior bariatric surgery
Implanted electrical stimulation devices (e.g. pacemaker, defibrillator, neurostimulator)
Unwillingness to stop medication altering gastric pH and/or affecting GI motility during the entire study duration.
Known diagnosed psychiatric conditions that may impair subject's ability to comply with the study procedures (by self-report)
Use of anti-psychotic medications
Diagnosed with an eating disorder including bulimia and binge eating
Swallowing difficulties
Significant active or unstable acute or chronic illnesses/ diseases including gastrointestinal, systemic (non-gastrointestinal) and psychiatric conditions
Use of another investigation device or agent in the 30 days prior to enrollment
Women who are pregnant, lactating or anticipate to becoming pregnant within the study duration
Planned or contemplated use of Magnetic Resonance Imaging (MRI) or any (e.g. oncologic) radiation during the course of the trial.
Have a family member who is currently participating in this clinical trial
Any other conditions that, in the opinion of the investigator, would make the subject unsuitable for the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Timna Naftali, MD
Organizational Affiliation
Meir Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Meir Medical Center
City
Kfar Saba
ZIP/Postal Code
4428164
Country
Israel
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Safety and Feasibility Assessment of the Bio-electrical One Day Capsule System in Overweight and Class I Obese Participants
We'll reach out to this number within 24 hrs